Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (11029)	11/13/1997 12:23:00 PM
From: chirodoc	Respond to of 32384

<<<<<<Might we assume that LLY's agreement with LGND had something to do with that upgrade? Say yes .........maybe (sorry) ........analysts love lilly's pipline--obviously they talk about knockout sales of prozac and other drugs for psychological problems. they expect big things from evista and feel that of all the big pharmas, they have one of the richest pipelines. ........that means to me that they think that lilly is good at spotting potential blockbusters and bringing them to market. i think that they would merely see ligand as a way of strengthening lilly's already rich pipeline--that's just my intuition. ......in my opinion, the high regard that analysts have for lilly will rub off as ligand receives business and technical support from lilly. any lilly influence on the culture of ligand will probably be beneficial--at least i hope that is so.